WallStreetZenWallStreetZen

NASDAQ: EXAI
Exscientia PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for EXAI

Based on 2 analysts offering 12 month price targets for Exscientia PLC.
Min Forecast
$5.00+2.04%
Avg Forecast
$6.00+22.45%
Max Forecast
$7.00+42.86%

Should I buy or sell EXAI stock?

Based on 2 analysts offering ratings for Exscientia PLC.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EXAI stock forecasts and price targets.

EXAI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-13
lockedlocked$00.00+00.00%2024-04-22

1 of 1

Forecast return on equity

Is EXAI forecast to generate an efficient return?
Company
-11.74%
Industry
-116.31%
Market
54.93%
EXAI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EXAI forecast to generate an efficient return on assets?
Company
-7.94%
Industry
24.06%
EXAI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EXAI earnings per share forecast

What is EXAI's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.25
Avg 2 year Forecast
-$1.12
Avg 3 year Forecast
-$0.36

EXAI revenue forecast

What is EXAI's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$51.4M+93.17%
Avg 2 year Forecast
$77.4M+190.88%
Avg 3 year Forecast
$80.1M+200.99%
EXAI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EXAI revenue growth forecast

How is EXAI forecast to perform vs Biotechnology companies and vs the US market?
Company
58.66%
Industry
53.36%
Market
8.17%
EXAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EXAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EXAI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EXAI$4.90$6.00+22.45%Hold
ATXS$11.12$25.20+126.62%Strong Buy
YMAB$13.82$21.14+52.99%Buy
HUMA$5.27$9.25+75.52%Strong Buy
ADPT$4.27$5.50+28.81%Strong Buy
View Top Biotech Stocks

Exscientia Stock Forecast FAQ

Is Exscientia Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: EXAI) stock is to Hold EXAI stock.

Out of 2 analysts, 0 (0%) are recommending EXAI as a Strong Buy, 0 (0%) are recommending EXAI as a Buy, 2 (100%) are recommending EXAI as a Hold, 0 (0%) are recommending EXAI as a Sell, and 0 (0%) are recommending EXAI as a Strong Sell.

If you're new to stock investing, here's how to buy Exscientia stock.

What is EXAI's earnings growth forecast for 2024-2026?

(NASDAQ: EXAI) Exscientia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.32%.

Exscientia's earnings in 2024 is -$170,519,736.On average, 2 Wall Street analysts forecast EXAI's earnings for 2024 to be -$158,137,049, with the lowest EXAI earnings forecast at -$158,772,138, and the highest EXAI earnings forecast at -$157,501,960. On average, 3 Wall Street analysts forecast EXAI's earnings for 2025 to be -$142,678,994, with the lowest EXAI earnings forecast at -$177,824,794, and the highest EXAI earnings forecast at -$95,263,283.

In 2026, EXAI is forecast to generate -$45,726,376 in earnings, with the lowest earnings forecast at -$45,726,376 and the highest earnings forecast at -$45,726,376.

What is EXAI's revenue growth forecast for 2024-2026?

(NASDAQ: EXAI) Exscientia's forecast annual revenue growth rate of 58.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 53.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.17%.

Exscientia's revenue in 2024 is $27,659,210.On average, 1 Wall Street analysts forecast EXAI's revenue for 2024 to be $6,528,710,294, with the lowest EXAI revenue forecast at $6,528,710,294, and the highest EXAI revenue forecast at $6,528,710,294. On average, 1 Wall Street analysts forecast EXAI's revenue for 2025 to be $9,831,170,754, with the lowest EXAI revenue forecast at $9,831,170,754, and the highest EXAI revenue forecast at $9,831,170,754.

In 2026, EXAI is forecast to generate $10,172,848,394 in revenue, with the lowest revenue forecast at $10,172,848,394 and the highest revenue forecast at $10,172,848,394.

What is EXAI's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: EXAI) forecast ROA is -7.94%, which is lower than the forecast US Biotechnology industry average of 24.06%.

What is EXAI's Price Target?

According to 2 Wall Street analysts that have issued a 1 year EXAI price target, the average EXAI price target is $6.00, with the highest EXAI stock price forecast at $7.00 and the lowest EXAI stock price forecast at $5.00.

On average, Wall Street analysts predict that Exscientia's share price could reach $6.00 by Aug 13, 2025. The average Exscientia stock price prediction forecasts a potential upside of 22.45% from the current EXAI share price of $4.90.

What is EXAI's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: EXAI) Exscientia's current Earnings Per Share (EPS) is -$1.37. On average, analysts forecast that EXAI's EPS will be -$1.25 for 2024, with the lowest EPS forecast at -$1.25, and the highest EPS forecast at -$1.24. On average, analysts forecast that EXAI's EPS will be -$1.12 for 2025, with the lowest EPS forecast at -$1.40, and the highest EPS forecast at -$0.75. In 2026, EXAI's EPS is forecast to hit -$0.36 (min: -$0.36, max: -$0.36).

What is EXAI's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: EXAI) forecast ROE is -11.74%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.